The IPO is entirely a fresh issue of 1 crore shares. Shares are expected to list on the BSE and NSE on September 8.
Amanta Healthcare IPO Subscription Status:
Within the first hour of Day 1 bidding, as of 10:03 AM, the IPO was overall subscribed 25%. Retail Individual Investors (RIIs) have subscribed to 33% of the 35 lakh shares on offer.Non-Institutional Investors (NIIs) have subscribed to 22% of the 15 lakh shares available. Qualified Institutional Buyers (QIBs) have yet to submit any bids for the 20 lakh shares allotted to them.
Amanta Healthcare IPO GMP Today
In the grey market, Amanta Healthcare shares are trading at a 15% premium over the upper end of the price band, which is set at Rs 126 per share, indicating positive investor sentiment ahead of the listing.Note : GMP refers to the premium at which an IPO share is trading in the unofficial market before its listing on the stock exchange. It reflects market sentiment and expected listing gains but is not an official or regulated indicator.
Amanta Healthcare IPO Details:
The issue will remain open for three days, closing on Wednesday. Based in Ahmedabad, Amanta Healthcare is a pharmaceutical company engaged in the production of sterile liquid formulations and medical devices. The company has set a price band of Rs 120–126 per share for the public offering.
The IPO is entirely a fresh issue of 1 crore shares. Shares are expected to list on the BSE and NSE on September 8.
About the Company
Amanta Healthcare specializes in the development and marketing of sterile injectables, IV fluids, ophthalmic solutions, respiratory care products, irrigation solutions, and medical devices. Its key technology platforms include SteriPort (ISBM) and ABFS (aseptic blow-fill-seal).
The company has established a robust domestic network with over 320 distributors and stockists, while also exporting its products to regions including Africa, Latin America, the UK, and other emerging markets. In FY25, approximately 55% of its revenue was generated from domestic branded generics, 33% from international sales, and 10% from product partnerships and contract manufacturing.
Amanta’s Hariyala facility in Gujarat is equipped with seven production lines for both Large Volume Parenterals (LVPs) and Small Volume Parenterals (SVPs), and holds certifications from regulatory authorities in India and abroad.
Financials
Amanta Healthcare reported consolidated revenue of Rs 274.7 crore in FY25, slightly down from Rs 280.3 crore in FY24. However, profit after tax saw a significant increase, rising to Rs 10.5 crore in FY25 from Rs 3.6 crore in the previous year.
IPO Objectives
The company intends to allocate Rs 70 crore of the IPO proceeds towards expanding its SteriPort manufacturing line, Rs 30.1 crore for establishing a new production line for Small Volume Parenterals (SVPs), with the remaining funds earmarked for general corporate purposes.
Should You Subscribe?
Investor4Edu recommends subscribing to the IPO, citing Amanta Healthcare’s strong potential to capitalize on the growing demand for sterile liquid pharmaceuticals and medical devices both in India and international markets.
At the upper price band, the stock is valued at approximately 47 times its post-issue FY25 earnings, indicating that the IPO may be fairly priced.
With certifications across 120 jurisdictions, a diverse product portfolio, and a clear focus on sterile pharmaceuticals, Amanta Healthcare is well-positioned for future growth. Subscription trends over the coming two days, along with grey market activity, will offer better insights ahead of the stock’s listing.
(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)
as a Reliable and Trusted News Source